

MEMORANDUM

Date: 3/18/2020

Re: Donor Screening and Deferral Actions in Response to Novel Coronavirus (2019-nCoV) Outbreak

JRF Ortho is a collaboration between two of the largest AATB accredited processors in the country, AlloSource and Community Tissue Services (CTS). Our role is to help facilitate distribution of allograft tissue through relationships with hospitals, surgical facilities, surgeons and field representatives.

JRF Ortho contracts donor screening, recovery, receipt, tissue processing, testing, release, storage, shipment and allograft tracking with AlloSource and CTS. As such, we received notice from them that as of the beginning of February they had updated their screening protocol related to the Coronavirus/Covid-19 outbreak.

Per guidance provided within the AATB Bulletin #20-3 published January 31, 2020, and titled "The AATB Physicians Council Issues Donor Screening and Deferral Recommendations to Tissue Bank Medical Directors Related to the Novel Coronavirus (2019-nCoV) Outbreak", AlloSource and CTS implemented appropriate donor screening measures and donor exclusion criteria for donors recovered after February 7, 2020.

The exclusion criteria listed in AATB Bulletin #20-3 is as follows:

AATB 2019-nCoV Donor Deferral for HCT/Ps

Donor exclusion for exposure to 2019-nCoV in last 28 days before donation

- Travel to China (regardless of symptoms), or
- Travel to other geographic area designated as area of active transmission by CDC* and (i) presentation of symptoms consistent with 2019-nCoV (e.g. unexplained fever, cough, diarrhea) or (ii) exposure link to suspected case patient while in the designated area, or
- Close contact with a person who has confirmed 2019-nCoV infection

3/18/2020

**DONOR SCREENING AND DEFERRAL ACTIONS IN RESPONSE TO
NOVEL CORONAVIRUS (2019-NCOV) OUTBREAK**



Donor exclusion for infection with 2019-nCoV in the last 28 days before donation

- Test positive for 2019-nCoV, or
- Symptoms consistent with active 2019-nCoV infection (e.g. unexplained fever, cough, diarrhea) in a patient with suspected 2019-nCoV infection

* <https://www.cdc.gov/coronavirus/2019-ncov/index.html>

Please know that we are doing everything we can to ensure the continued safety of our allograft tissue, and our processors swiftly incorporate any new guidance that is presented by the FDA and AATB regarding this matter.

Sincerely,

A handwritten signature in blue ink that reads "Dina Pasquino".

Dina Pasquino
Chief Compliance Officer & Director of Operations
JRF Ortho